Prominent IP Updates on Jan 13, 2015

Dicerna Pharma (DRNA) Receives U.S. Patent Covering DsiRNA-EX

Dicerna Pharma announced that the United States Patent and Trademark Office (USPTO) issued to Dicerna Patent No. 8,927,705, “Single Stranded Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression”.

Microsoft patents eye-tracking system for head-mounted display

Microsoft was recently rumored to working on a head-mounted virtual reality headset for the Xbox One. The company recently patented an eye-tracking system for head-mounted display. The head-mounted display will images “close to the user’s eyes”.

Bristol-Myers Squibb, Natco Pharma settle patent dispute

The patent dispute between US-based pharma major Bristol-Myers Squibb (BMS) and Indian pharma company Natco Pharma Ltd over entecavir, a pharmaceutical combination for treating Hepatitis B has been settled amicably, both the companies informed Intellectual Property Appellate Board (IPAB).

Siemens named in Wobben patent suit

Siemens has been named in the suit, alongside Dong Energy and A2Sea and the companies which own Westermost Rough and Gunfleet Sands. The legal action has been brought by Wobben Properties.

Oxis Biotech Executes Worldwide Exclusive Patent Licensing with University of Pittsburgh Professor

Oxis International, Inc. a biotechnology company focused on cannabinoid therapy development and commercialization, announced today, wholly owned subsidiary Oxis Biotech, Inc. executed definitive agreements licensing certain assets for the treatment of Multiple Myeloma and initiated a consulting agreement with University of Pittsburgh’s Professor, Dr. Xiang-Qun(Sean)Xie.

New drug delivery technology from MIPS acquired by Capsugel

Capsugel and Monash University announced today that Capsugel has acquired the intellectual property pertaining to proprietary Ionic Liquids Technology developed at the Monash Institute of Pharmaceutical Sciences (MIPS), Monash University.

Ralco gets patent for shrimp farming raceways

American agriculture nutrition company Ralco has announced Texas A&M University has licensed the company’s patent for a shrimp raceway system.

Chimerix receives notice of allowance for Brincidofovir patent

Chimerix announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent application covering a method of synthesis and the commercial morphic form of brincidofovir.

AVT Announces that New Patented EndCap System Unveiled at CES will be Exhibited at Upcoming NAMA Show

AVT, Inc., a manufacturer of Automated Retailing Systems and Smart Vending Machines with patented technologies, announced that their new EndCap Automated Retailing System, which gained acclaim at the Consumer Electronics Show in Las Vegas, will be exhibited at the 2015 NAMA One Show.

Metrics Scientist Awarded Patent for Zero-Order Release Tablet Technology

The U.S. Patent and Trademark Office awarded Dr. Thomas B. “Brad” Gold a patent (No. 8,858,993) for his application, “Coated tablets with zero-order or near zero-order release kinetics

PetVivo Announces The Continued Expansion Of Gel-Del’s Intellectual Property Portfolio

PetVivo Holdings, Inc. an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices and therapeutics for pets is pleased to announce the continued expansion of the patent portfolio of its merging partner Gel-Del Technologies, Inc.

Biocide Systems Prevails in Chlorine Dioxide Technology Patent Infringement Lawsuit

The Patent infringement law suit, Case No.13-60136-CIV-MIDDLEBROOKS/BRANNON, filed by Odorstar Technology LLC and Kinpak lnc. a wholly owned subsidiary of Ocean Bio-Chem, was first filed on Jan. 18, 2013 in the U.S. District Court for the Southern District of Florida, alleging Biocide Systems CLO2-DMG Technology was infringing on their NosGuard US Patent number 6,764661

Drug humira turns rheumatic for abbott biotechnology

The Indian Patent Office on December 31, 2014 set aside its order of granting a Patent to Abbott Biotechnology for its drug, Humira, in light of pre-grant opposition filed by Glenmark Pharmaceuticals. In November, 2003, Abbott had filed a patent application No. 526/DELNP/2005 for its drug named Humira, a formulation of human antibodies for treating Rheumatoid Arthritis